CACLP - The largest IVD Expo & Conference

Roche Nabs FDA Clearance for Alzheimer's Assays

Industry news | 28 June, 2023 | CACLP

Original from: 360DX

 

Roche said Tuesday that it secured US Food and Drug Administration 510(k) clearances for a pair of assays to aid diagnosis of Alzheimer's disease measuring levels of beta-amyloid and tau proteins. 

 

The Basel, Switzerland-based firm's Elecsys beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys Total-Tau CSF (tTau) assays are used together to provide the ratio of tTau and Abeta42 proteins in evaluating adults ages 55 and older for Alzheimer's disease. Roche also received clearance in December 2022 for use of the Abeta42 assay and its Elecsys Phospho-Tau (181P) CSF immunoassay, which are used together to identify a patient's ratio of Abeta42 and pTau181 proteins. 

 

Roche said Tuesday the ratios measured with the assays reflect the main Alzheimer's pathologies of amyloid plaques, tau tangles, and neurodegeneration, and the assays can help clinicians more completely define a patient's disease. Changes in the biomarker levels also can help identifyAlzheimer's pathology in earlier stages. 

 

The Abeta42 and pTau181 assays are available and the tTau and Abeta42 assay combination will be available in the fourth quarter of 2023, the firm said. The assays are designed for use on Roche's fully automated Cobas immunoassay instruments. 

 

"An early and accurate diagnosis can help patients, caregivers, and physicians determine a path forward, and the Elecsys CSF assays support diagnosis at early disease stages, when treatment is most effective," Roche Diagnostics North America CEO Brad Moore said in a statement. 

 

The firm noted that the Abeta42 and tTau assays are intended to be used along with other clinical evaluations. 

 

The firm said its Elecsys AD CSF assays are concordant with amyloid PET scan imaging and can provide a more affordable, accessible routine method of confirming amyloid pathology through a single CSF draw. The assays are CE marked and registered in a total of 46 countries. Roche also secured FDA breakthrough device designation in 2022 for its Elecsys Amyloid Plasma Panel for measuring Alzheimer's biomarkers from blood samples, although those assays remain under development. ​​​​

 

Source: Roche Nabs FDA Clearance for Alzheimer's Assays

 

Filed under:
Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference